AAREYDRUGS vs HIKAL: Stock Comparison
Aarey Drugs & Pharmaceuticals Limited vs Hikal Limited
Live data: 29 April 2026, 4:01 PM IST • Source: NSE and company filings
Hikal Limited is the larger company by market capitalisation. Aarey Drugs & Pharmaceuticals Limited shows lower leverage, a higher ROCE and a higher net margin, while Hikal Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of Aarey Drugs & Pharmaceuticals Limited and Hikal Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AAREYDRUGS | HIKAL |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AAREYDRUGS | HIKAL |
|---|---|---|
| Live Price | ₹90.51 | ₹213.16 |
| Day Change | -4.92% | -5.15% |
| Volume | 2.2 L | 3.55 L |
| 52-Week High | ₹96 | ₹343.85 |
| 52-Week Low | ₹50.31 | ₹146.25 |
| Distance from 52W High | -5.72% | -38.01% |
Valuation
| Metric | AAREYDRUGS | HIKAL |
|---|---|---|
| Market Cap | ₹221 Cr | ₹2,637 Cr |
| P/E Ratio | 55.36x | -56.64x |
| P/B Ratio | 1.46x | 2.31x |
| EPS | ₹1.47 | ₹-3.95 |
| Book Value | ₹48.67 | ₹97.4 |
| Dividend Yield | 0% | 0.44% |
Growth
| Metric | AAREYDRUGS | HIKAL |
|---|---|---|
| Revenue Growth (TTM YoY) | 19.8% | 37.3% |
| EPS Growth (TTM YoY) | -41.05% | 68.3% |
| Qtr Sales Growth | 0% | -5.97% |
| Qtr Profit Growth | 0% | 22.5% |
Profitability & Leverage
| Metric | AAREYDRUGS | HIKAL |
|---|---|---|
| ROE | 2.64% | 2.95% |
| ROCE | 6% | 3.52% |
| Net Margin | 0.84% | -2.88% |
| Operating Margin | 2.21% | 12.9% |
| Debt to Equity | 0.33x | 0.57x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | AAREYDRUGS | HIKAL |
|---|---|---|
| Promoter Holding | 37.71%▼ 1.35 pp | 68.85% |
| FII Holding | 4.18%▲ 0.32 pp | 1.43%▼ 0.87 pp |
| DII Holding | 1.62%▲ 1.62 pp | 7.2%▲ 0.15 pp |
| Public Holding | 56.49%▼ 0.6 pp | 22.52%▲ 0.73 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarey Drugs & Pharmaceuticals Limited and Hikal Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.